Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders. Petros Pharmaceuticals Inc., formerly known as Neurotrope Inc., is based in NEW YORK.
Info & Links
CEO
Joshua N. Silverman
Headquarters
1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK, NY 10036, UNITED STATES
Petros Pharmaceuticals, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
2.05M
Enterprise Value
5.59M
Enterprise Value/EBITDA(ttm)
-0.47
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.43
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
74.56%
Operating Margin(ttm)
--
Profit Margin(ttm)
-647.62%
Return on Equity(ttm)
-78.22%
Return on Invested Capital(ttm)
78.44%
Return on Assets(ttm)
-23.50%
Income Statement
Revenue(ttm)
5.11M
Revenue Per Share(ttm)
0.10
Gross Profit(ttm)
3.90M
EBITDA(ttm)3
-11.77M
Net Income Available to Common(ttm)
-26.80M
Diluted EPS(ttm)
-4.76
Share Statistics
Beta (5Y Monthly)
1.84
52-Week Change
-93.58%
S&P 500 52-Week Change
3.55%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
53.52M
Dividend Yield
0.00%
Float4
9.93M
% Held by Insiders
12.25%
% Held by Institutions
12.34%
Balance Sheet
Total Cash(mrq)
3.71M
Total Cash Per Share(mrq)
0.07
Total Debt(mrq)
7.25M
Total Debt/Equity(mrq)
-97.07%
Current Ratio(mrq)
0.40%
Quick Ratio(mrq)
0.74%
Book Value Per Share(mrq)
-0.71
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.32
Free Cash Flow(ytd)
-2.63M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.